[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

June 27, 2019
Original Investigation

Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers

Abstract Full Text
JAMA Oncol. Published online June 27, 2019. doi:10.1001/jamaoncol.2019.1208

This review of data from 75 families with a CDH1 pathologic variant compares estimates of the lifetime risk of gastric cancer in the families found to have a CDH1 pathologic variant through clinical ascertainment with those ascertained through multigene panel testing.

Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers

Abstract Full Text
has audio
JAMA Oncol. Published online June 27, 2019. doi:10.1001/jamaoncol.2019.1402

This cohort study uses data from the Southern Community Cohort Study to evaluate whether race-specific adjustment of pack-year criteria in the US Preventive Services Task Force (USPSTF) lung cancer screening guidelines is associated with more equitable screening for African American smokers at high risk for lung cancer.

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study

Abstract Full Text
open access
JAMA Oncol. Published online June 27, 2019. doi:10.1001/jamaoncol.2019.1011

This open-label, phase 2 randomized clinical trial assesses the safety of abiraterone acetate combined with 4 glucocorticoid regimens for treatment of metastatic castration-resistant prostate cancer.

Research Letter

Effect of Introducing a Default Order in the Electronic Medical Record on Unnecessary Daily Imaging During Palliative Radiotherapy for Adults With Cancer: A Stepped-Wedge Cluster Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online June 27, 2019. doi:10.1001/jamaoncol.2019.1432

This randomized clinical trial examines the effect of implementing a default order option in the electronic medical record on daily imaging utilization for patients with cancer undergoing radiotherapy during palliative care.

JAMA Oncology Clinical Challenge

A New Brain Mass in an Immunocompromised Woman

Abstract Full Text
JAMA Oncol. Published online June 27, 2019. doi:10.1001/jamaoncol.2019.1042

A woman in her 30s with a history of a renal transplant presented with right-sided, lower-extremity weakness and intermittent confusion. What is your diagnosis?

Viewpoint

Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?

Abstract Full Text
JAMA Oncol. Published online June 27, 2019. doi:10.1001/jamaoncol.2019.1598

This Viewpoint presents 4 arguments against routinely substituting zoledronic acid with denosumab in patients with newly diagnosed multiple myeloma.

Invited Commentary

Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges

Abstract Full Text
JAMA Oncol. Published online June 27, 2019. doi:10.1001/jamaoncol.2019.1008
Comment & Response

Looking Forward, Not Backward, on Watch and Wait for Rectal Cancer

Abstract Full Text
JAMA Oncol. Published online June 27, 2019. doi:10.1001/jamaoncol.2019.1867

Looking Forward, Not Backward, on Watch and Wait for Rectal Cancer—In Reply

Abstract Full Text
JAMA Oncol. Published online June 27, 2019. doi:10.1001/jamaoncol.2019.1887
June 20, 2019
Original Investigation

Association Between Birth Defects and Cancer Risk Among Children and Adolescents in a Population-Based Assessment of 10 Million Live Births

Abstract Full Text
JAMA Oncol. Published online June 20, 2019. doi:10.1001/jamaoncol.2019.1215

This population-based study links data registries on births, birth defects, and cancer diagnoses in 10 million live births in 4 US states to identify associations between birth defects and childhood cancer diagnoses and to characterize cancer risk in children with 1 or more birth defects.

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online June 20, 2019. doi:10.1001/jamaoncol.2019.1179

This phase 2 randomized clinical trial investigates the effects of adding lapatinib to perioperative epirubicin, cisplatin, and capecitabine chemotherapy in patients with potentially curable HER2-positive gastroesophageal adenocarcinoma.

Association Between Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia

Abstract Full Text
JAMA Oncol. Published online June 20, 2019. doi:10.1001/jamaoncol.2019.1094

This cohort study examines the neurocognitive and neuroimaging outcomes associated with multiple use of general anesthesia in survivors of childhood acute lymphoblastic leukemia.

Research Letter

Prevalence of Chronic Pain and High-Impact Chronic Pain in Cancer Survivors in the United States

Abstract Full Text
JAMA Oncol. Published online June 20, 2019. doi:10.1001/jamaoncol.2019.1439

This survey study uses data from the National Health Interview Survey to investigate the prevalence of, and socioeconomic risk factors for, chronic pain and high-impact chronic pain among cancer survivors in the United States.

Viewpoint

Interventional Pharmacoeconomics—A New Discipline for a Cost-Constrained Environment

Abstract Full Text
JAMA Oncol. Published online June 20, 2019. doi:10.1001/jamaoncol.2019.1341

This Viewpoint describes strategies and challenges for interventional pharmacoeconomics to reduce prescribing costs while maintaining efficacy.

Editorial

Birth Defects and Cancer in Childhood—Dual Diseases of Development

Abstract Full Text
JAMA Oncol. Published online June 20, 2019. doi:10.1001/jamaoncol.2019.1207
Comment & Response

Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?

Abstract Full Text
JAMA Oncol. Published online June 20, 2019. doi:10.1001/jamaoncol.2019.1326

Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?—In Reply

Abstract Full Text
JAMA Oncol. Published online June 20, 2019. doi:10.1001/jamaoncol.2019.1332
Correction

Errors in Data Presentation in Text, Figures, Table, and eTables

Abstract Full Text
free access
JAMA Oncol. Published online June 20, 2019. doi:10.1001/jamaoncol.2019.2422
June 13, 2019
Original Investigation

Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Abstract Full Text
open access
JAMA Oncol. Published online June 13, 2019. doi:10.1001/jamaoncol.2019.1029

This open-label phase 2 clinical trial evaluates the clinical activity and safety of combination niraparib and pembrolizumab treatment in women with advanced or metastatic triple-negative breast cancer.

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Abstract Full Text
open access
JAMA Oncol. Published online June 13, 2019. doi:10.1001/jamaoncol.2019.1048

This open-label, single-arm, phases 1 and 2 study evaluates the poly(adenosine diphosphate–ribose) polymerase inhibitor niraparib combined with pembrolizumab in patients with recurrent ovarian carcinoma.

Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online June 13, 2019. doi:10.1001/jamaoncol.2019.1146

This randomized clinical trial assesses the effect of afatinib vs placebo after definitive chemoradiotherapy on disease-free survival in patients with head and neck squamous cell carcinoma.

Editorial

Immune Checkpoint and Poly(ADP–Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers

Abstract Full Text
JAMA Oncol. Published online June 13, 2019. doi:10.1001/jamaoncol.2019.1009
Comment & Response

Becoming a Statistic in the Middle of an Epidemic—A Call to Consider Alternate Risk Factors for Early-Onset Colorectal Cancer

Abstract Full Text
JAMA Oncol. Published online June 13, 2019. doi:10.1001/jamaoncol.2019.1320

Becoming a Statistic in the Middle of an Epidemic—A Call to Consider Alternate Risk Factors for Early-Onset Colorectal Cancer

Abstract Full Text
JAMA Oncol. Published online June 13, 2019. doi:10.1001/jamaoncol.2019.1323

Becoming a Statistic in the Middle of an Epidemic—A Call to Consider Alternate Risk Factors for Early-Onset Colorectal Cancer—In Reply

Abstract Full Text
JAMA Oncol. Published online June 13, 2019. doi:10.1001/jamaoncol.2019.1329
Correction

Incorrect Data in the Abstract and a Figure Caption

Abstract Full Text
free access
JAMA Oncol. Published online June 13, 2019. doi:10.1001/jamaoncol.2019.2162
June 6, 2019
Original Investigation

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Abstract Full Text
JAMA Oncol. Published online June 6, 2019. doi:10.1001/jamaoncol.2019.1022

This cohort study evaluates the feasibility, risks, and advantages of resuming immune checkpoint inhibitor therapy in patients with cancer who experienced severe immune-related adverse events.

Comment & Response

Survivorship Bias in Analyses of Immune Checkpoint Inhibitor Trials

Abstract Full Text
JAMA Oncol. Published online June 6, 2019. doi:10.1001/jamaoncol.2019.1187

Survivorship Bias in Analyses of Immune Checkpoint Inhibitor Trials—In Reply

Abstract Full Text
JAMA Oncol. Published online June 6, 2019. doi:10.1001/jamaoncol.2019.1190
June 3, 2019
Brief Report

Factors Associated With Age Disparities Among Cancer Clinical Trial Participants

Abstract Full Text
has multimedia
JAMA Oncol. Published online June 3, 2019. doi:10.1001/jamaoncol.2019.2055

This study characterizes the age disparities among trial enrollees in randomized clinical trials of common cancers (breast, prostate, colorectal, and lung cancer) in US population-based median age and identifies factors associated with age imbalances.

June 2, 2019
Original Investigation

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

Abstract Full Text
has multimedia
JAMA Oncol. Published online June 2, 2019. doi:10.1001/jamaoncol.2019.2244

This open-label, nonrandomized, phase 1 study assesses the safety of pembrolizumab in patients with HIV and advanced cancer.

June 1, 2019
Research Letter

Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer

Abstract Full Text
has multimedia
JAMA Oncol. Published online June 1, 2019. doi:10.1001/jamaoncol.2019.1943

This study assesses tumor-stroma proportion and compares this finding with the development of resistance to platinum-based chemotherapy in women newly diagnosed with ovarian carcinoma.

×